Molecular mechanisms of RET-induced Hirschsprung pathogenesis

Annals of Medicine

Volumn 38, Issue 1, 2006, Pages 11-19

  Lantieri, Francesca ^a,b   Griseri, Paola ^a   Ceccherini, Isabella ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Apoptosis; Complex inheritance; Disease predisposition; Genetic counselling; Hirschsprung disease; Loss of function; Molecular pathogenesis; RET proto oncogene; RNA splicing; Transcription regulation

Indexed keywords

PROTEIN RET;

ALLELE; APOPTOSIS; DISEASE COURSE; DNA POLYMORPHISM; EXON; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HIRSCHSPRUNG DISEASE; HUMAN; INTRON; NONHUMAN; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTO ONCOGENE; REVIEW; RNA SPLICING; TRANSCRIPTION REGULATION;

APOPTOSIS; GENE EXPRESSION; HIRSCHSPRUNG DISEASE; HUMANS; MITOGENS; MUTATION; POLYMORPHISM, GENETIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; RNA;

EID: 31744442077     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890500442758     Document Type: Review

References (51)

1. Chakravarti A, Lyonnet S. Hirschsprung Disease. In: Scriver CR, Beaudet AL, Valle D, Sly WS, Childs B, Kinzler KW, et al., editors, . The Metabolic & Molecular Bases of Inherited Disease, Eighth International Edition vol. IV. New York: McGraw-Hill, 2001. p 6231-55.
2. Badner JA, Sieber WK, Garver KL, Chakravarti A. A genetic study of Hirschsprung disease. Am J Hum Genet. 1990;46:568-80.
3. Martucciello G, Bicocchi MP, Dodero P, Lerone M, Cirillo MS, Puliti A, et al. Total colonic aganglionosis associated with interstitial deletion of the long arm of chromosome 10. Pediatr Surg Int. 1992;7:308-10.
4. Luo Y, Ceccherini I, Pasini B, Matera I, Bicocchi MP, Barone V, et al. Close linkage with the RET protooncogene and boundaries of deletion mutations in autosomal dominant Hirschsprung disease. Hum Mol Genet. 1993;2:1803-08.
5. Fewtrell MS, Tam PK, Thomson AH, Fitchett M, Currie J, Huson SM, et al. Hirschsprung's disease associated with a deletion of chromosome 10 (q11.2q21.2): a further link with the neurocristopathies? J Med Genet. 1994;31:325-7.
6. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET protooncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458-60.
7. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851-6.
8. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985;42:581-8.
9. Ceccherini I, Bocciardi R, Luo Y, Pasini B, Hofstra R, Takahashi M, et al. Exon structure and flanking intronic sequences of the human RET proto-oncogene. Biochem Biophys Res Commun. 1993;196:1288-95.
10. Myers SM, Eng C, Ponder BA, Mulligan LM. Characterization of RET proto-oncogene 3′ splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene. 1995;11:2039-45.
11. De Graaf E, Sriniva S, Kilknny C, D'Agati V, Mankoo B, Costantini F, et al. Differential activities of the RET tyrosine - kinase recptor isoforms during mammmalian embryogenesis. Genes Dev. 2001;15:2433-44.
12. Scott RP, Eketjall S, Aineskog H, Ibanez CF. Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase. J Biol Chem. 2005;280:13442-9.
13. Anders J, Kjar S, Ibanez CF. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J Biol Chem. 2001;276:35808-17.
14. Airaksinen MS, Titievsky A, Saarma M. GDNF family neurotrophic factor signaling: four masters, one servant? Mol Cell Neurosci. 1999;13:313-25. Review.
15. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005;16:441-67.
16. Angrist M, Bolk S, Thiel B, Puffenberger EG, Hofstra RM, Buys CH, et al. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease. Hum Mol Genet. 1995;4:821-30.
17. Attie T, Pelet A, Edery P, Eng C, Mulligan LM, Amiel J, et al. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet. 1995;4:1381-6.
18. Seri M, Yin L, Barone V, Bolino A, Celli I, Bocciardi R, et al. Frequency of RET mutations in long- and short-segment Hirschsprung disease. Hum Mutat. 1997;9:243-9.
19. Kashuk CS, Stone EA, Grice EA, Portnoy ME, Green ED, Sidow A, et al. Phenotype-genotype correlation in Hirschsprung disease is illuminated by comparative analysis of the RET protein sequence. Proc Natl Acad Sci U S A. 2005;102:8949-54.
20. Pasini B, Borrello MG, Greco A, Bongarzone I, Luo Y, Mondellini P, et al. Loss of function effect of RET mutations causing Hirschsprung disease. Nat Genet. 1995;10: 35-40.
21. Carlomagno F, De Vita G, Berlingieri MT, de Franciscis V, Melillo RM, Colantuoni V, et al. Molecular heterogeneity of RET loss of function in Hirschsprung's disease. EMBO J. 1996;15:2717-25.
22. Pelet A, Geneste O, Edery P, Pasini A, Chappuis S, Atti T, et al. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease. J Clin Invest. 1998;101:1415-23.
23. Geneste O, Bidaud C, De Vita G, Hofstra RM, Tartare-Deckert S, Buys CH, et al. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site. Hum Mol Genet. 1999;8:1989-99.
24. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol. 1995;15:1613-9.
25. Iwashita T, Murakami H, Asai N, Takahashi M. Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain. Hum Mol Genet. 1996;5:1577-80.
26. Cosma MP, Cardone M, Carlomagno F, Colantuoni V. Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism. Mol Cell Biol. 1998;18:3321-9.
27. Kjaer S, Ibanez CF. Intrinsic susceptibility to misfolding of a hot-spot for Hirschsprung disease mutations in the ectodomain of RET. Hum Mol Genet. 2003;12:2133-44.
28. Bordeaux MC, Forcet C, Granger L, Corset V, Bidaud C, Billaud M, et al. The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease. EMBO J. 2000;19:4056-63.
29. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276:1575-9.
30. Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Franciscis V, et al. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res. 1997;57:391-5.
31. Takahashi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM, Billaud M. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function? Hum Mutat. 1999;13:331-6.
32. Mograbi B, Bocciardi R, Bourget I, Juhel T, Farahi-Far D, Romeo G, et al. The sensitivity of activated Cys Ret mutants to glial cell line-derived neurotrophic factor is mandatory to rescue neuroectodermic cells from apoptosis. Mol Cell Biol. 2001;21:6719-30.
33. Arighi E, Popsueva A, Degl'Innocenti D, Borrello MG, Carniti C, Perala NM, et al. Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease. Mol Endocrinol. 2004;18:1004-17.
34. Decker RA, Peacock ML, Watson P. Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet. 1998;7:129-34.
35. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet. 2002;3:285-98.
36. Griseri P, Mishto M, Priolo M, Pesce B, Hamel BJ, Ravazzolo R, et al. An intronic nucleotide variant of the RET proto-oncogene causes Hirschsprung disease by interfering with RNA splicing. Gene Funct Dis. 2000;5-6:184-8.
37. Auricchio A, Griseri P, Carpentieri ML, Betsos N, Staiano A, Tozzi A, et al. Double Heterozygosity for a RET Substitution Interfering with Splicing and an EDNRB Missense Mutation in Hirschsprung Disease. Am J Hum Genet. 1999;64: 1216-21.
38. Bolk S, Pelet A, Hofstra RM, Angrist M, Salomon R, Croaker D, et al. A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus. Proc Natl Acad Sci U S A. 2000;97:268-73.
39. Borrego S, Saez ME, Ruiz A, Gimm O, Lopez-Alonso M, Antinolo G, et al. Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet. 1999;36:771-4.
40. Griseri P, Sancandi M, Patrone G, Bocciardi R, Hofstra R, Ravazzolo R, et al. A single-nucleotide polymorphic variant of the RET proto-oncogene is underrepresented in sporadic Hirschsprung disease. Eur J Hum Genet. 2000;8:721-4.
41. Fitze G, Cramer J, Ziegler A, Schierz M, Schreiber M, Kuhlisch E, et al. Association between c135G/A genotype and RET proto-oncogene germline mutations and phenotype of Hirschsprung's disease. Lancet. 2002;359:1200-5.
42. Borrego S, Ruiz A, Saez ME, Gimm O, Gao X, Lopez-Alonso M, et al. RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease. J Med Genet. 2000;37:572-8.
43. Carrasquillo MM, McCallion AS, Puffenberger EG, Kashuk CS, Nouri N, Chakravarti A. Genome-wide association study and mouse model identify interaction between RET and EDNRB pathways in Hirschsprung disease. Nat Genet. 2002;32:237-44.
44. Fitze G, Appelt H, Konig IR, Gorgens H, Stein U, Walther W, et al. Functional haplotypes of the RET proto-oncogene promoter are associated with Hirschsprung disease (HSCR). Hum Mol Genet. 2003;12:3207-14.
45. Sancandi M, Griseri P, Pesce B, Patrone G, Puppo F, Lerone M, et al. Single nucleotide polymorphic alleles in the 5′ region of the RET proto-oncogene define a risk haplotype in Hirschsprung's disease. J Med Genet. 2003;40: 714-8.
46. Borrego S, Wright FA, Fernandez RM, Williams N, Lopez-Alonso M, Davuluri R, et al. A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma. Am J Hum Genet. 2003;72:88-100.
47. Garcia-Barcelo M, Ganster RW, Lui VC, Leon TY, So MT, Lau AM, et al. TTF-1 and RET promoter SNPs: regulation of RET transcription in Hirschsprung's disease. Hum Mol Genet. 2005;14:191-204.
48. Griseri P, Bachetti T, Puppo F, Lantieri F, Ravazzolo R, Devoto M, et al. A common haplotype at the 5′ end of the RET proto-oncogene, overrepresented in Hirschsprung patients, is associated with reduced gene expression. Hum Mutat. 2005;25:189-95.
49. Burzynski GM, Nolte IM, Bronda A, Bos KK, Osinga J, Plaza Menacho I, et al. Identifying candidate Hirschsprung disease-associated RET variants. Am J Hum Genet. 2005;76:850-8.
50. Emison ES, McCallion AS, Kashuk CS, Bush RT, Grice E, Lin S, et al. A common sex-dependent mutation in a RET enhancer underlies Hirschsprung disease risk. Nature. 2005;434:857-63.
51. Puppo F, Musso M, Pirulli D, Griseri P, Bachetti T, Crovella S, et al., Comparative genomic sequence analysis coupled to Chromatin Immunoprecipitation: a screening procedure applied to search for regulatory elements at the RET locus. Physiol Genomics. 2005;23:269-74.